SkinBioTherapeutics (GB:SBTX) has released an update.
SkinBioTherapeutics plc has finalized the conversion of its £5.0 million convertible bond facility by issuing 5,848,620 new ordinary shares, with the admission of these shares to AIM expected on 26 July 2024. The company decided against further draws from the facility respecting shareholder sentiment and has successfully cleared the bond with the support of existing and new institutional investors. The total voting rights in the company will now be based on 211,210,526 issued shares post-admission.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.
